Lipocine
LPCN
39 hedge funds and large institutions have $10.5M invested in Lipocine in 2021 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 7 increasing their positions, 12 reducing their positions, and 7 closing their positions.
676% more call options, than puts
Call options by funds: $1.11M | Put options by funds: $143K
14% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 7
5% more capital invested
Capital invested by funds: $10M → $10.5M (+$506K)
3% more funds holding
Funds holding: 38 → 39 (+1)
0.1% more ownership
Funds ownership: 0.61% → 0.71% (+0.1%)
42% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 12
Top Buyers
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$137K |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$137K |
| 3 |
Two Sigma Investments
New York
|
+$112K |
| 4 |
VF
Virtu Financial
New York
|
+$95.5K |
| 5 |
Two Sigma Advisers
New York
|
+$57.9K |
Top Sellers
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
-$371K |
| 2 |
Morgan Stanley
New York
|
-$213K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$31K |
| 4 |
Barclays
London,
United Kingdom
|
-$26K |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$26K |
LPCN Hedge Fund Activity: Q4 2021 in Review
39 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Lipocine (LPCN) for Q4 2021, worth a combined $10.5M — up 5.1% from $10M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new LPCN positions and 7 closed out — a net gain of 1 holder — while 7 added to existing stakes and 12 trimmed.
The largest buyer was Susquehanna International Group, adding an estimated $137K. The largest seller was Ameriprise, cutting an estimated $371K.
- 39 institutional investors held Lipocine (LPCN) as of Q4 2021, up from 38 in Q3 2021.
- Funds reported $10.5M of Lipocine stock for Q4 2021, up 5.1% quarter-over-quarter.
- 8 funds opened new Lipocine positions in Q4 2021 and 7 closed out, a net change of +1 holder.
- The largest Lipocine buyer in Q4 2021 was Susquehanna International Group, an estimated $137K added.
- The largest Lipocine seller in Q4 2021 was Ameriprise, an estimated $371K sold.
Based on aggregated 13F filings for Q4 2021.